about
Safe handling of oral antineoplastic medications: focus on targeted therapeutics in the home settingA pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemiasSorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells.Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunitiesPresent and future evolution of advanced breast cancer therapy.Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma.Emerging therapies for adult soft tissue sarcoma.From a multipotent stilbene to soluble epoxide hydrolase inhibitors with antiproliferative properties.Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1.Raf kinases: oncogenesis and drug discovery.Chemotherapy and targeted molecular therapies for brain metastases.Efficacy of BIBF 1120 or BIBF 1120 plus chemotherapy on nasopharyngeal carcinoma in vitro and in vivoSignal-transduction inhibitors in renal cell carcinoma.New approaches in metastatic melanoma: biological and molecular targeted therapies.Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation.Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activationBCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing.Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms.Role of chemokines and their receptors in chronic lymphocytic leukemia: function in microenvironment and targeted therapy.Characterizing nanoscale changes in the activity of VEGFR-2 on glioma microvascular endothelial cell membranes using atomic force microscopy.New anti-angiogenic strategies in pediatric solid malignancies: agents and biomarkers of a near future.Anti-angiogenic therapy in glioma.Tyrosine kinase inhibitors and drug interactions: a review with practical recommendations.Sorafenib in melanoma.Novel targeted agents for the treatment of advanced breast cancer.Sorafenib for ovarian cancer.Sorafenib for the treatment of multiple myeloma.Converting biology into clinical benefit: lessons learned from BRAF inhibitors.The role of death receptor 3 in the biological behavior of hepatocellular carcinoma cells.Antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642EVorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway.Sorafenib combined vitamin K induces apoptosis in human pancreatic cancer cell lines through RAF/MEK/ERK and c-Jun NH2-terminal kinase pathways.Radiofrequency ablation or percutaneous ethanol injection for the treatment of liver tumors.Regulation of autophagy by ceramide-CD95-PERK signaling.Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization.Efficacy and safety of sorafenib for advanced renal cell carcinoma: real-world data of patients with renal impairment.
P2860
Q23923997-DAD5CF66-2526-4035-9CF1-E22E9A9D6C0CQ34063343-CBC32D21-2724-4FBD-931C-AF5CD8775076Q34104350-D52EE857-8DEB-4520-BC3E-6343B1F3856CQ34139691-27A48209-1209-4FA7-AAA4-321021DD9385Q34274925-63B52C52-EAB6-4560-8974-40F9FD92D38AQ34647911-EE4E118B-6360-4D37-B493-2013BC8FEA40Q34659806-46255467-0F11-456D-BF5C-378EA8915D90Q34675957-0FF309D3-2B22-44B6-A331-826444F8B745Q35080145-8926B012-CE7E-4EA4-9003-DAECC4240E4CQ36559414-3CA7B303-1EA0-4D82-A0DE-07D8FDD2DA37Q36641504-C2D19842-48AE-4A69-AB6F-D9BC72BB2DEDQ36710062-0920423F-41BB-41BC-8F8D-580F90F5F1A2Q36794811-9AF3F29C-3969-44F7-ABB9-B14898B4D7E6Q36817127-BE17AFB4-4917-4C6D-942F-47F8FDBEBF11Q36922674-4B26FE9D-D5CD-49CC-A283-6CC974C6A39EQ37172903-0811986C-7FBC-47A0-B402-8205A076EC43Q37268123-EDD7FAC2-88DA-4B8B-A38C-6B8EE8ABD346Q37268127-01D0D3A9-18F9-4972-A9B5-EFBE11986842Q37610087-02B8016A-8534-4E83-ABB1-7F0E7481EEC3Q37697604-F1FB295F-8E4E-4C7D-96AF-F63052F6DA57Q37752435-6D4C4D91-361E-4E7D-A4EA-93B74BCACC70Q37877409-E6948AD2-05C7-4FAB-8415-FB138166DC76Q37981002-9A54E728-CE98-4A5D-A4B5-760F39997FC1Q37990977-1C45FD39-B6C0-4936-95A6-A88BEB2A6659Q38008723-440BEB97-9D02-4E4B-B3F0-FB993919C71DQ38106994-548708DA-790A-4DD8-8E67-7264FCB75E2CQ38783055-A6D2C121-C3EE-4D69-B841-5C755DD71564Q38940098-CEE43E07-4A73-4343-AB42-114C4DB93BE7Q38942768-DBF03092-4981-4C18-BB3A-90F4DEA3D439Q39610381-9547C752-8225-4488-80A0-C007BACB8073Q39680200-1B3E35B4-6681-4EB6-AEDE-D62AD78E997DQ39725762-F111D9F0-81C6-4875-9FD3-376656616296Q42592749-A8A30263-9311-4967-AA52-0613D45ABCF8Q42613657-3F33BE06-22F8-4328-9D67-C6B1A5B494E9Q43753506-EE9FF902-6E76-496E-9A08-F6B64B72A4D6Q52714334-D720FA17-A8B7-4F02-A0E5-759E10AF8AAB
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Sorafenib.
@ast
Sorafenib.
@en
type
label
Sorafenib.
@ast
Sorafenib.
@en
prefLabel
Sorafenib.
@ast
Sorafenib.
@en
P2860
P356
P1476
Sorafenib.
@en
P2093
Brian I Rini
P2860
P304
P356
10.1517/14656566.7.4.453
P407
P577
2006-03-01T00:00:00Z